Trial Now Recruiting: A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations (NCT06706076)
WHY IT MATTERS
This trial is now actively recruiting patients with EGFR and/or HER2-mutated advanced NSCLC — if you have this genetic profile and have exhausted standard treatments, you may be eligible to access a potentially new treatment option.
Researchers are testing a new drug called BH-30643 for advanced lung cancer patients whose tumors have specific genetic mutations (EGFR or HER2). The study will first figure out the right dose and watch for side effects, then test how well the drug works against the cancer. About 266 patients will participate across multiple hospitals.
NCT ID: NCT06706076 Status: RECRUITING Conditions: NSCLC (Advanced Non-small Cell Lung Cancer) Phase: PHASE1, PHASE2 Enrollment: 266 Sponsor: BlossomHill Therapeutics Summary: This Phase1/2, open label, multicenter study will assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics and preliminary anti-tumor activity of BH-30643 in patients with NSCLC having EGFR and/or HER2 mutations. Phase 1 will determine the recommended Phase 2 dose (RP2D) and, if applicable, the maximum tolerated dose (MTD) of BH-30643. Phase 2 will further evaluate the antitumor efficacy and safety in specified cohorts determined by EGFR/HER2 mutation subtypes and/or treatment
YOU CAN ACT ON THIS
If you have advanced NSCLC with EGFR or HER2 mutations, ask your oncologist immediately whether you meet the eligibility criteria for NCT06706076, as sites are actively enrolling now.